01 November 2006
Leptin increases proliferation of human osteosarcoma cells through activation of PI(3)-K and MAPK pathways
Bartolome Burguera, Amy Brunetto, Adolfo Garcia-Ocana, Roseta Teijeiro, James Esplen, Thierry Thomas, Marta E. Couce, Allan ZhaoMed Sci Monit 2006; 12(11): BR341-349 :: ID: 462552
Abstract
Background: Serum leptin levels are strongly and directly related to fat body mass (FBM). Bone mineral density(BMD) increases with FBM, and obesity has a protective effect against osteoporosis. We have previously demonstrated that leptin therapy has a signifi cant effect in preventing ovariectomy-induced
bone loss in rats and leptin also exerts direct osteogenic effects in vitro. To obtain a better understanding of the physiology and pharmacology of leptin in bone metabolism, we evaluated the leptin-induced signal transduction pathways and proliferative response in the human osteosarcoma cell line Saos-2.
Material/Methods: Saos-2 cell lines were used. Leptin receptor common form (OB-Ra) and long form (OB-Rb) were detected by RT-PCR and immunocytochemistry. PI(3)-K activity was immunoprecipitated using antibodies
directed against tyrosine-phosphorylated proteins and IRS-1. The activated form of p42/p44 MAPK was investigated in cytosolic extracts of confl uent Saos-2 in response to leptin.
Results: In this study, we tested the hypothesis that leptin might be a mediator linking obesity and bone
cell proliferation. We found that Saos-2 cells expressed OB-Ra and OB-Rb. Leptin (10 nmol/L –
2 umol/L) caused a signifi cant increase in the activation of PI(3)-K that was accompanied by an
increase in cell proliferation dose dependently based on the [[sup]3[/sup]H]-thymidine incorporation. The
specifi c PI(3)-K inhibitors LY294002 and wortmannin blocked leptin-induced cell proliferation.
Interestingly, leptin activated MAPK and the specifi c MAPK-inhibitor PD98059 blocked DNA synthesis
induced by leptin.
Conclusions: Our data support the hypothesis that leptin may increase bone mass by stimulating osteoblast proliferation through activation of the PI(3)-K and MAPK signaling pathways.
Keywords: Bone and Bones - metabolism, Enzyme Inhibitors - pharmacology, Insulin Receptor Substrate Proteins, Leptin - physiology, Osteosarcoma - pathology, Phosphatidylinositol 3-Kinases - metabolism, Phosphoproteins - metabolism, Phosphorylation, Tyrosine - chemistry
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Evaluation of Attitudes to Learning Doctor-Patient Communication Skills in 427 Postgraduate Doctors Using t...Med Sci Monit In Press; DOI: 10.12659/MSM.947276
Clinical Research
Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study ...Med Sci Monit In Press; DOI: 10.12659/MSM.947703
Clinical Research
Comparative Analysis of Laser Therapies for Striae Distensae: Fractional COâ‚‚ vs Combined Q-Switch Nd:YAGMed Sci Monit In Press; DOI: 10.12659/MSM.947464
Database Analysis
Utility of Central Venous Oxygen Saturation Gradient in Predicting Mortality in Dialysis with Catheter AccessMed Sci Monit In Press; DOI: 10.12659/MSM.947298
Most Viewed Current Articles
17 Jan 2024 : Review article 7,082,464
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,311
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,546
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 21,733
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912